These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2752109)

  • 1. Molecular defects of factor IX Chicago-2 (Arg 145----His) and prothrombin Madrid (Arg 271----cys): arginine mutations that preclude zymogen activation.
    Diuguid DL; Rabiet MJ; Furie BC; Furie B
    Blood; 1989 Jul; 74(1):193-200. PubMed ID: 2752109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
    Noyes CM; Griffith MJ; Roberts HR; Lundblad RL
    Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4200-2. PubMed ID: 6603618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273.
    Rabiet MJ; Furie BC; Furie B
    J Biol Chem; 1986 Nov; 261(32):15045-8. PubMed ID: 3771562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase.
    Suehiro K; Kawabata S; Miyata T; Takeya H; Takamatsu J; Ogata K; Kamiya T; Saito H; Niho Y; Iwanaga S
    J Biol Chem; 1989 Dec; 264(35):21257-65. PubMed ID: 2592373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo.
    Monroe DM; McCord DM; Huang MN; High KA; Lundblad RL; Kasper CK; Roberts HR
    Blood; 1989 May; 73(6):1540-4. PubMed ID: 2713493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
    Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
    Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
    Bertina RM; van der Linden IK; Mannucci PM; Reinalda-Poot HH; Cupers R; Poort SR; Reitsma PH
    J Biol Chem; 1990 Jul; 265(19):10876-83. PubMed ID: 2162822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
    Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
    J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
    Sakai T; Yoshioka A; Yamamoto K; Niinomi K; Fujimura Y; Fukui H; Miyata T; Iwanaga S
    J Biochem; 1989 May; 105(5):756-9. PubMed ID: 2753873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
    de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
    Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of normal and abnormal human factor IX with trypsin.
    Monroe DM; Noyes CM; Straight DL; Roberts HR; Griffith MJ
    Arch Biochem Biophys; 1985 May; 238(2):490-6. PubMed ID: 3873217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme.
    Lenting PJ; ter Maat H; Clijsters PP; Donath MJ; van Mourik JA; Mertens K
    J Biol Chem; 1995 Jun; 270(25):14884-90. PubMed ID: 7797466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity.
    Bharadwaj D; Iino M; Kontoyianni M; Smith KJ; Foster DC; Kisiel W
    J Biol Chem; 1996 Nov; 271(48):30685-91. PubMed ID: 8940045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation.
    Wojcik EG; van den Berg M; van der Linden IK; Poort SR; Cupers R; Bertina RM
    Biochem J; 1995 Nov; 311 ( Pt 3)(Pt 3):753-9. PubMed ID: 7487929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propeptide processing during factor IX biosynthesis. Effect of point mutations adjacent to the propeptide cleavage site.
    Bristol JA; Furie BC; Furie B
    J Biol Chem; 1993 Apr; 268(10):7577-84. PubMed ID: 8463288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin Tokushima, a replacement of arginine-418 by tryptophan that impairs the fibrinogen clotting activity of derived thrombin Tokushima.
    Miyata T; Morita T; Inomoto T; Kawauchi S; Shirakami A; Iwanaga S
    Biochemistry; 1987 Feb; 26(4):1117-22. PubMed ID: 3567158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three distinct point mutations in the factor IX gene of three Japanese CRM+ hemophilia B patients (factor IX BMNagoya 2, factor IX Nagoya 3 and 4).
    Hamaguchi M; Matsushita T; Tanimoto M; Takahashi I; Yamamoto K; Sugiura I; Takamatsu J; Ogata K; Kamiya T; Saito H
    Thromb Haemost; 1991 May; 65(5):514-20. PubMed ID: 1871712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia B(M) by synthetic peptides.
    Takahashi I; Kojima T; Sano M; Watanabe T; Kamiya T; Saito H
    Peptides; 2000 May; 21(5):603-8. PubMed ID: 10876041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide.
    Huang MN; Kasper CK; Roberts HR; Stafford DW; High KA
    Blood; 1989 Feb; 73(3):718-21. PubMed ID: 2563663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
    Ware J; Diuguid DL; Liebman HA; Rabiet MJ; Kasper CK; Furie BC; Furie B; Stafford DW
    J Biol Chem; 1989 Jul; 264(19):11401-6. PubMed ID: 2738071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.